Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.59
-1.6%
$5.39
$3.96
$9.85
$2.48B0.412.60 million shs1.05 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.45
+3.7%
$16.26
$13.75
$55.70
$1.42B0.911.30 million shs2.08 million shs
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$21.09
+15.6%
$18.70
$13.37
$32.27
$586.92M1.38267,972 shs1.37 million shs
Vericel Corporation stock logo
VCEL
Vericel
$41.50
+3.3%
$41.78
$37.39
$63.00
$2.02B1.32418,346 shs413,446 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-1.79%-7.31%+35.04%+51.32%-8.41%
Biohaven Ltd. stock logo
BHVN
Biohaven
+3.96%-2.17%-15.38%-15.46%-58.98%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
+15.56%+14.74%+15.94%+35.19%-26.28%
Vericel Corporation stock logo
VCEL
Vericel
+3.31%+0.10%-5.29%-0.95%-9.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
3.6927 of 5 stars
1.93.00.04.02.33.30.6
Biohaven Ltd. stock logo
BHVN
Biohaven
3.1821 of 5 stars
4.51.00.00.01.82.50.6
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
1.5707 of 5 stars
3.60.00.00.03.30.80.0
Vericel Corporation stock logo
VCEL
Vericel
2.9479 of 5 stars
3.51.00.00.03.30.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.83
Reduce$7.3010.77% Upside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46304.58% Upside
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.13
Buy$53.00151.30% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1447.33% Upside

Current Analyst Ratings Breakdown

Latest DNTH, VCEL, BHC, and BHVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.00
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.00
5/13/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.00
5/13/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
5/2/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00
4/28/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.73B0.25$7.57 per share0.87($0.89) per share-7.40
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$6.24M108.69N/AN/A$11.91 per share1.77
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.81$0.32 per share128.55$5.92 per share7.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M-$0.11N/A1.41N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,383.7994.32N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest DNTH, VCEL, BHC, and BHVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.04N/AN/AN/A$64.61 millionN/A
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.9320N/AN/AN/A$2.47 billionN/A
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/12/2025Q1 2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.35
0.97
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
15.98
15.99
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
8.05%
Biohaven Ltd. stock logo
BHVN
Biohaven
16.00%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8.15%
Vericel Corporation stock logo
VCEL
Vericel
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.08 million340.29 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million85.78 millionOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8032.16 million29.54 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million47.73 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.59 -0.11 (-1.64%)
Closing price 07/9/2025 03:57 PM Eastern
Extended Trading
$6.55 -0.04 (-0.61%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Biohaven stock logo

Biohaven NYSE:BHVN

$14.45 +0.51 (+3.66%)
Closing price 07/9/2025 03:57 PM Eastern
Extended Trading
$14.84 +0.39 (+2.66%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$21.09 +2.84 (+15.56%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$20.98 -0.11 (-0.52%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Vericel stock logo

Vericel NASDAQ:VCEL

$41.50 +1.33 (+3.31%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$42.12 +0.63 (+1.51%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.